Dr. Margaret Cuomo is the author of “A World Without Cancer: The Making of a New Cure and the Real Promise of Prevention;” she is a board-certified radiologist who served as an attending physician in diagnostic radiology at North Shore University Hospital in Manhasset, N.Y. for many years. She was the keynote speaker at the T.J. Martell Foundation’s inaugural Women of Influence Awards at Riverpark in New York City.
We are honored to share her perspective here on Angelina Jolie’s courageous decision regarding the discovery of her BRCA1 genetic mutation and subsequent bilateral (aka “double”) mastectomy, as well as the implications for the cancer community.
Dr. Margaret Cuomo is the author of “A World Without Cancer: The Making of a New Cure and the Real Promise of Prevention.”
Angelina Jolie has my admiration for her courage in publicly describing her decision to undergo a bilateral (aka “double”) mastectomy. Her BRCA1 genetic mutation significantly increases her risk of developing breast cancer and ovarian cancer.
According to Jolie’s New York Times op-ed piece, her doctors estimated that she has an 87 percent risk of breast cancer and a 50 percent risk of ovarian cancer. Women who have inherited BRCA1 and BRCA2 mutations account for 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers (for white women) in the United States, according to the National Cancer Institute.
Knowing that her own mother died at the age of 56 following her battle with cancer, Angelina Jolie, the mother of six children, decided to be pro-active, and decided to sharply reduce her risk of breast cancer by undergoing the mastectomy.
The question that I hope many women are asking is: “Is this the best that we can do in the 21st century?” After 41 years and more than 90 billion dollars spent since the War on Cancer was declared, we should expect more effective and less invasive solutions to reducing breast cancer, and all cancers.
Are the National Cancer Institute and the pharmaceutical industry committing enough of their intellectual and financial resources to the discovery of safe, new ways of detecting breast cancer and ovarian cancer in their earliest stages? If a patient has a BRCA1 or BRACA2 mutation, are there techniques available to “turn-off” the faulty genes?
Is there a sense of urgency about finding new tests to detect breast cancer and ovarian cancer, and other cancers, that do not involve radiation – a known carcinogen?
The prevention of cancer should be our ultimate goal and it should have the full benefit of the National Cancer Institute’s and industry’s vast resources.
Our children are our future, and we should expect that their generation will prevent cancer without the traumatic solution that Angelina Jolie felt obliged to accept.